Company: BNBX
Filing Date: 2025-01-17
Form Type: 424B3
Source: 0001104659-25-004510
Chunk: 10

Company: BNB PLUS CORP.
Filing Date: 2025-01-17
Form: 424B3
Chunk 10
---
2026, dependent upon the availability of future funding and customer demand (“GMP Site 2”).
GMP is a quality standard used globally and by the U.S. Food and Drug Administration (“FDA”) to ensure pharmaceutical quality.
Drug substances are the pharmaceutically active components of drug products.

Segment Business Strategy

Our business strategy for our Therapeutic
DNA Production Services is to capitalize upon the rapid growth of mRNA therapies in the near term via our planned near term future availability
of LineaDNA IVT templates manufactured under GMP at our GMP Site 1, while at the same time laying the basis for additional clinical and
commercial applications of LineaDNA with our future planned availability of LineaDNA manufactured under GMP suitable for use as, or incorporation
into, a biologic, drug substance and/or drug product at planned GMP Site 2. Planned GMP Site 2 may also be used for additional LineaDNA
IVT template manufacturing if customer demand exceeds capacity of GMP Site 1. In addition, we believe GMP Site 1 is capable of manufacturing
LineaDNA for use as, or incorporation into, a biologic, drug substance, and/or drug product manufacturing via facility upgrades to its
existing footprint.

Our current plan is: (i) through our
Linea IVT platform and planned near term future GMP manufacturing capabilities for IVT templates at GMP Site 1 to secure commercial-scale
supply contracts with clinical and commercial mRNA and/or self-amplifying mRNA (“sa-RNA”) manufacturers for LineaDNA IVT
templates and/or Linea RNAP as critical starting materials; (ii) to utilize our current GLP production capacity for non-IVT template
applications to secure supply and/or development contracts with pre-clinical therapy developers that use DNA in their therapy manufacturing,
and (iii) upon our development of our planned future LineaDNA production under GMP suitable for use as, or incorporation into, a
biologic, drug substance and/or drug product at planned GMP Site 2 and/or our upgrade to GMP Site 1, to convert existing and new LineaDNA
customers into large-scale supply contracts to supply LineaDNA for clinical and commercial use as, or incorporation into, a biologic,
drug substance and/or drug product in a wide range of nucleic acid therapies. In addition, the Company plans to utilize its planned DNA
manufacturing capabilities in GMP Site 1 and/or GMP Site 2 to convert